Elevated Lp(a) contributes to pro-inflammatory gene expression of monocytes in both healthy subjects and CVD patients. Potent Lp(a)-lowering reduced the pro-inflammatory state of circulating monocytes.

Elevated TRL-c levels were associated with increased risk of MI and PAD in women, whereas high sdLDL-c levels were associated with increased risk of MI alone, as shown in a case-cohort study.

Total (first and subsequent) vascular events among patients with recent stroke or transient ischemic attack were reduced, as shown in a post-hoc analysis of the SPARCL trial.

High intake of sugar-sweetened beverages was associated with adverse changes in HDL-c and triglyceride, along with higher incidence of dyslipidemias related to low HDL-c and high triglyceride.

This post hoc analysis of the DM-DYSLIPIDEMIA study shows that, in a high risk subgroup of T2DM patients with mixed dyslipidemia, alirocumab treatment is more effective in reducing ApoB and non-HDL-c as compared to usual treatment.

Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital, that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.

In the past, there has been confusion about the relationship between HDL-c and CV risk and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.

At the end of the FOURIER trial, participants filled out a questionnaire on their memory, cognitive and executive function. No differences on cognition were noted between treatment groups.

Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

A subanalysis of FOURIER found that patients with recent MI (<12 months) had greater relative and absolute treatment benefit of evolocumab than those with remote MI.

The new ESC/EAS Dyslipidaemia Guidelines focus on high-risk patients, and prof. Laufs shares evidence for the treatment recommendations. Test your knowledge

Robert Giugliano explains that very low LDL-c levels are safe, using data of recent clinical trials with LDL-c lowering drugs.